Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 10/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5773713 | 0.84 | GABRA5 (0.50) | GABRA5ALDH1A1NPSR1PKMMAPT | |
| SCHEMBL256699 | 0.84 | PTGS1 (0.59) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL286512 | 0.83 | GABRA5 (0.49) | PTGS1PTGS2GABRA5ALDH1A1KMT2A | |
| SCHEMBL935024 | 0.82 | PTGS1 (0.58) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL107436 | 0.82 | PTGS1 (0.58) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL286436 | 0.82 | PTGS1 (0.58) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| Water SCHEMBL27477176 | 0.81 | PTGS1 (0.56) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL12844155 | 0.81 | PTGS1 (0.56) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL5018927 | 0.79 | PTGS1 (0.54) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL18885135 | 0.79 | GABRA5 (0.65) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427459-B1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-2767536-B1 | Isoxazolo-pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2015-09-02 | — | — | EP | disclosed |
| US-9073908-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2227467-B1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-8877783-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877782-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-8846719-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2767536-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-20130281690-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130274467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-7476667-B2 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2009-01-13 | — | — | US | disclosed |
| US-20080255100-A1 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| US-7405215-B2 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1805171-A2 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | Athersys, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070099916-A1 | Indolyl derivatives as liver-x-receptor (LXR) modulators | DEHMLOW HENRIETTA | 2007-05-03 | — | — | US | disclosed |
| CN-1950365-A | Indolyl derivatives as liver-X-receptor modulators | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | CN | disclosed |
| US-7173048-B2 | Indolyl derivatives as liver-X-receptor (LXR) modulators | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060100425-A1 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | ATHERSYS, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006034419-A2 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | ATHERSYS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20050245515-A1 | Indolyl derivatives as liver-X-receptor (LXR) modulators | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100425-A1 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | PTGDR2, TBXA2R, HCAR2 | PTGS1 88/4885PTGS2 23/4885GABRA5 522/4885 |
| US-20050245515-A1 | Indolyl derivatives as liver-X-receptor (LXR) modulators | INSR, NR1H2, NR1H3 | PTGS1 1237/4885PTGS2 2785/4885GABRA5 1957/4885 |
| US-20080255100-A1 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | PTGDR2, TBXA2R, HCAR2 | PTGS1 88/4885PTGS2 23/4885GABRA5 522/4885 |
| US-20070099916-A1 | Indolyl derivatives as liver-x-receptor (LXR) modulators | INSR, NR1H2, NR1H3 | PTGS1 1237/4885PTGS2 2785/4885GABRA5 1957/4885 |
| US-20130274467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | PTGS1 2445/4885PTGS2 3560/4885GABRA5 1/4885 |
| US-20130281690-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | PTGS1 2445/4885PTGS2 3560/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.